Tirzepatide

Overview

Tirzepatide is a once-weekly peptide that activates two incretin receptors at once, GIP and GLP-1, which is why it is described as a dual agonist rather than a single GLP-1 drug like semaglutide. Activating both pathways amplifies glucose-dependent insulin release, suppresses glucagon, slows how fast the stomach empties and reduces appetite. It reaches the market as two FDA-approved Eli Lilly products: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea.

Evidence Quality

The evidence base is unusually strong for a metabolic peptide. Approval rested on the large SURPASS program in diabetes and the SURMOUNT program in obesity, both consisting of multi-thousand-participant randomized controlled trials with results published in The New England Journal of Medicine. This places tirzepatide in the top tier of evidence quality, comparable to established prescription drugs rather than experimental compounds.

What the Research Shows

In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes lost on average about 16% of body weight at 5 mg, 21% at 10 mg and 22.5% at 15 mg after 72 weeks, versus roughly 2.4% on placebo. In SURPASS-2, tirzepatide lowered HbA1c by roughly 2.0 to 2.5 points and produced greater weight loss than semaglutide 1 mg. The later SURMOUNT-5 head-to-head trial found tirzepatide produced significantly more weight loss than semaglutide in people with obesity. A recurring caveat across GLP-1-class agents is that some of the weight lost is lean muscle, which resistance training and adequate protein help preserve.

Dosage Notes

The label uses a slow, stepwise ramp. Treatment starts at 2.5 mg once weekly, a deliberately non-therapeutic starter dose meant only to let the gut adapt. After at least four weeks the dose rises to 5 mg, and thereafter it can increase in 2.5 mg steps no sooner than every four weeks, up to a maximum of 15 mg weekly. Most people settle at whatever dose gives good results with tolerable side effects rather than automatically climbing to 15 mg.

Who Should Be Cautious

Tirzepatide carries a boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should be avoided or used with care in people with a history of pancreatitis, severe gastrointestinal disease or gastroparesis, and it is not for type 1 diabetes. Caution is warranted with insulin or sulfonylureas because of hypoglycemia risk, and during pregnancy or breastfeeding.

Availability

As a prescription medicine, tirzepatide is dispensed as Mounjaro and Zepbound in pre-filled pens and single-dose vials. It is also sold in lyophilized 'research chemical' vials, such as a 10 mg lyophilized powder in a 3 mL glass vial, which are labeled for laboratory research and marked 'not for human consumption.' These research-grade products are not FDA-approved, are not manufactured to pharmaceutical standards, and carry no guarantee of identity, purity or sterility.

Bottom Line

Tirzepatide is one of the most effective metabolic peptides yet studied, backed by an exceptionally strong clinical trial record and full FDA approval as Mounjaro and Zepbound. The tradeoffs are frequent gastrointestinal side effects, potential loss of muscle mass, a thyroid-tumor boxed warning, and the fact that research-chemical versions fall entirely outside regulatory oversight.